Navigation Links
Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO)
Date:1/12/2009

ABBOTT PARK, Ill. and SANTA ANA, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Advanced Medical Optics (AMO) (NYSE: EYE) announced today a definitive agreement for Abbott to acquire AMO for $22 per share in cash, for a total transaction value of approximately $2.8 billion, inclusive of estimated net debt at the time of closing. Based in Santa Ana, Calif., AMO is a global leader in ophthalmic care, comprised of three segments: cataract surgery, laser vision correction (LASIK), and eye care products. Globally, AMO holds the number one position in LASIK surgical devices, the number two position in the cataract surgical device market and the number three position in contact lens care products.

"Through superior vision care technologies and service, AMO has established itself as a leader in this multi-billion dollar medical device segment. With AMO, Abbott is enhancing and strengthening its diverse mix of medical device businesses and gaining a leadership position in another large and growing segment," said Miles D. White, chairman and chief executive officer, Abbott. "Additionally, Abbott's significant global presence will help drive growth opportunities for this business, especially in international markets, where favorable demographics are driving demand for advanced eye care procedures and products."

"This transaction underscores the fundamental value of the AMO franchise, the talent and expertise of our global team, and the strength of our product offering, pipeline and strategy to provide refractive vision care for people of all ag
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Abbott Announces Earnings Guidance for 2009
2. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
3. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
4. Abbotts XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
5. Abbott Hosts Conference Call for Third-Quarter Earnings
6. Abbott to Present at UBS Best of Americas Investment Conference
7. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
8. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
9. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
10. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
11. Abbott Invests Additional $20M in Isis Subsidiary Ibis Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
(Date:1/14/2014)... January 14, 2014 Independent publisher Bitingduck ... and Montreal, Canada, has big ideas for 2014 in ... press's goals are to produce high-quality, low-cost, DRM-free ebooks ... local businesses. , The first major development will ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... 12 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... and,nine months ended Sept. 30, 2007. Third ... for the third quarter and nine months ended ... respectively, compared with $16.5 million,and $30.2 million, respectively, ...
... Fla., Nov. 12 GeoPharma, Inc. (Nasdaq:,GORX) (the ... an,approval from the FDA to begin producing Carprofen. ... is a,non-steroidal anti-inflammatory drug (NSAID) that is used ... associated with osteoarthritis in,dogs. Additionally, Carprofen is often ...
... Toronto Stock Exchange Symbol: MS, EDMONTON, Nov. ... leading developer in the treatment of multiple sclerosis ... been enrolled in its MAESTRO-03,U.S. pivotal phase III ... progressive multiple sclerosis (SPMS). An interim safety and,efficacy ...
Cached Biology Technology:Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 4Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 5Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 6GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen 2GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen 3BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 2BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 3
(Date:4/17/2014)... the process whereby the genetic information of DNA ... proteins, which have numerous different functions in living ... intermediary during gene expression, by relating the genetic ... in manufacturing proteins. , By examining the ... in an organism at a given time, researchers ...
(Date:4/17/2014)... National University (ANU), have developed a new way ... over the past 5.3 million years., The findings ... ice ages over the past two million years, ... dioxide levels, global temperatures and sea levels., The ... and the National Oceanography Centre (NOC) in the ...
(Date:4/16/2014)... collections two new species of yellow-shouldered bats have been unearthed by ... Museum of Natural History and described in the open access journal ... genus Sturnira are part of a recent discovery of ... one still waiting to be officially announced. , Up until recently ...
Breaking Biology News(10 mins):Rapid and accurate mRNA detection in plant tissues 2Ancient sea-levels give new clues on ice ages 2Two new species of yellow-shouldered bats endemic to the Neotropics 2
... and bees may do it, but the microscopic animals called ... thank you. Whats more, they have done so over millions ... These hardy creatures somehow escape the usual drawback of asexuality ... Meselson, and their colleagues are finding out how. ...
... to permanent paralysis and loss of sensation below the site ... The nerve fibers or axons have the capacity to grow ... develops around the injury. Northwestern University researchers have ... of scar tissue at the injury site and enables the ...
... available in French . , Modern ... of the worlds water flows, with potentially sudden and ... them researchers at the Stockholm University-affiliated Stockholm Resilience Centre ... published April 1 in the journal Trends in Ecology ...
Cached Biology News:Is DNA repair a substitute for sex? 2Is DNA repair a substitute for sex? 3Promising new nanotechnology for spinal cord injury 2Sudden 'ecosystem flips' imperil world's poorest regions, say water experts 2Sudden 'ecosystem flips' imperil world's poorest regions, say water experts 3
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
interferon-related developmental regulator 2...
Biology Products: